Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma
- 1 June 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (6) , 835-842
Abstract
PURPOSE: Financial toxicity is a contributor to the psychosocial burden of cancer care. There is no consensus measure of financial toxicity; however, recent studies have adopted the Comprehensive Score for Financial Toxicity (COST). Despite its growing popularity, data on the responsiveness to change of the COST instrument are lacking. To address this gap in the literature, we performed a sequential mixed-methods study of people with multiple myeloma. MATERIALS AND METHODS: In the quantitative phase of the study, we collected COST scores at two time points approximately 8 weeks apart from 72 patients. In the qualitative phase, we conducted semistructured interviews with a subset of 12 patients who reported the largest changes in scores. The qualitative data were analyzed using a deductive coding scheme developed using the Framework Method in the context of a commonly cited conceptual model of financial toxicity. RESULTS: The median absolute change in COST scores was four points (IQR, 2-6). Only 13% of the sample had the same COST scores at both assessments; 38% had an improved score and 50% had a worsened score. Only, seven of the 12 patients (58%) interviewed reported changes to one or more of the constructs in the conceptual model of financial toxicity. Most commonly, changes to out-of-pocket medical costs were reported (5/12). Changes to nonmedical expenses (n = 2) and subjective financial distress without changes to objective financial burden (n = 2) were also reported. CONCLUSION: Additional research is needed to explicate changes in COST scores over time.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Financial Toxicity and Its Association With Health-Related Quality of Life Among Partners of Colorectal Cancer SurvivorsJAMA Network Open, 2023
- The Dynamics of Financial Toxicity in Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2023
- Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-AnalysisValue in Health, 2022
- Out-of-Pocket Costs Among Patients With a New Cancer Diagnosis Enrolled in High-Deductible Health Plans vs Traditional InsuranceJAMA Network Open, 2021
- The COmprehensive Score for financial Toxicity in China: Validation and ResponsivenessJournal of Pain and Symptom Management, 2021
- Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsThe Oncologist, 2021
- Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of lifeAnnals of Oncology, 2020
- Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implicationsAnnals of Oncology, 2019
- Financial Hardships Experienced by Cancer Survivors: A Systematic ReviewJNCI: Journal of the National Cancer Institute, 2016
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Cancer, 2016